Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer

[1]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[2]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[3]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms of action and resistance in breast cancer , 1997, Breast Cancer Research and Treatment.

[4]  M. Beato,et al.  Interaction of steroid hormone receptors with the transcription initiation complex. , 1996, Endocrine reviews.

[5]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Katzenellenbogen,et al.  Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. O’Malley,et al.  CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[9]  J. Foekens,et al.  Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources , 1996, International journal of cancer.

[10]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[11]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[12]  J. Foekens,et al.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. , 1994, British Journal of Cancer.

[13]  J. Foekens,et al.  Cell biological factors associated with the response of breast cancer to systemic treatment. , 1993, Cancer treatment reviews.

[14]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[16]  R. Gibbs,et al.  Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[17]  大草 康.  胃癌の浸潤転移におけるurokinase type plasminogen activator(uPA)の意義に関する研究 : uPA活性発現における癌細胞並びに腫瘍間質細胞の役割と相互作用に着目して , 2000 .

[18]  J. Foekens,et al.  Prognostic factors and response to therapy in breast cancer. , 1993, Cancer surveys.